1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide;N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide;N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
• 化学式: C31H41N5O2S2
• 分子量: 579.8
• InChiKey: SALQGHOSZMXMSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.56
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Sumatriptan promethazine pharmaceutical compositions
  申请人：Charleston Laboratories, Inc.

  公开号：US10772840B2

  公开（公告）日：2020-09-15

  Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, photophobia, or adverse effects associated with the headache. Also provided herein are small smooth particulates comprising a 5HT1B/1D receptor agonist. Compositions for oral administration are described herein wherein the compositions comprise a combination of active agents, such as a 5HT1B/1D receptor agonist and one or more antiemetics.

  提供了治疗头痛、头痛相关症状、畏光或头痛相关不良反应的药物组合物和方法。本文还提供了包含 5HT1B/1D 受体激动剂的小光滑微粒。本文描述了用于口服给药的组合物，其中组合物包含活性剂的组合，如5HT1B/1D受体激动剂和一种或多种止吐药。
• PHARMACEUTICAL COMPOSITIONS
  申请人：Charleston Laboratories, Inc.

  公开号：EP3191093A1

  公开（公告）日：2017-07-19
• [EN] PHARMACEUTICAL COMPOSITIONS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES
  申请人：CHARLESTON LAB INC

  公开号：WO2016040358A1

  公开（公告）日：2016-03-17

  Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, or adverse effects associated with triptan administration.